MARKET

IMRN

IMRN

Immuron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.15
+0.39
+6.77%
Pre Market: 6.48 +0.33 +5.37% 08:12 03/08 EST
OPEN
5.95
PREV CLOSE
5.76
HIGH
6.50
LOW
5.41
VOLUME
384
TURNOVER
--
52 WEEK HIGH
28.99
52 WEEK LOW
1.550
MARKET CAP
34.88M
P/E (TTM)
-5.8338
1D
5D
1M
3M
1Y
5Y
Human Microbiome Modulators Market Share, Demand, Industry Analysis, Growth, Applications, Types and Forecasts Report 2027
Mar 04, 2021 (AB Digital via COMTEX) -- The global Human Microbiome Modulators Market is forecasted to be worth USD 5.24 Billion by 2027, according...
ABNewswire · 3d ago
Immuron (ASX:IMC) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 5d ago
Global Antiprotozoal Drugs Market 2020 Analysis by Key Players, End-User, Type, Application, Regions and Forecast to 2025
Feb 15, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has announced the addition of a new report entitled Global Antiprotozoal Drugs Market 2020...
CDN Newswire · 02/15 23:18
Worldwide Hyperlipidemia Drugs Industry to 2025 - by Drug Type, End-user and Region
Dublin, Feb 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 12, 2021 (GLOBE NEWSWIRE) -- The "Hyperlipidemia Drugs Market: Global Industry Trends,...
GlobeNewswire · 02/12 11:23
Hyperlipidemia Prescription Drugs Market 2020 By Manufacturers, Regions, Type, Application And Forecast Till 2027
Comserve · 02/11 05:39
$1.1 Bn Alcoholic Hepatitis Therapeutics Market – Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2027
Feb 03, 2021 (Market Insight Reports) -- The global Alcoholic Hepatitis Therapeutics market is expected to grow at a CAGR of around 5.3% over the forecast...
Market Insight Reports · 02/03 08:08
Alcoholic Hepatitis Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 02, 2021 (Market Insight Reports) -- The report for Alcoholic Hepatitis Therapeutics offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 02/02 14:23
Covid-19 Impact: Bacillary Dysentery Drug Market To Grow At A Much Faster Rate Beyond 2020| Financial Analysis And Forecast
Jan 29, 2021 (MarketResearch.biz via Comtex) -- Bacillary Dysentery Drug Businesses must navigate the financial and operational challenges of coronavirus...
marketresearch.biz · 01/29 06:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRN. Analyze the recent business situations of Immuron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMRN stock price target is 6.56 with a high estimate of 6.56 and a low estimate of 6.56.
EPS
Institutional Holdings
Institutions: 10
Institutional Holdings: 192.35K
% Owned: 3.39%
Shares Outstanding: 5.67M
TypeInstitutionsShares
Increased
1
637
New
2
-14.29K
Decreased
1
1.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Roger Aston
Chief Executive Officer/Chief Operating Officer/Chief Scientific Officer
Jerry Kanellos
Vice Chairman/Director
Peter Anastasiou
Secretary
Phillip Hains
Secretary
Peter Vaughan
Director
Richard Berman
Director
Ravi Savarirayan
Non-Executive Director
Stephen Anastasiou
Non-Executive Director
Daniel Pollock
No Data
  • All
  • Financials
  • Insiders
No Data
About IMRN
Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

Webull offers kinds of Immuron Ltd stock information, including NASDAQ:IMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRN stock methods without spending real money on the virtual paper trading platform.